, Volume 39, Issue 1, pp 51-52

Large subretinal hemorrhage after intravitreal bevacizumab (Avastin®) for age-related macular degeneration

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

We report the development of a large subretinal hemorrhage 4 weeks after intravitreal bevacizumab in an 84-year-old male with 20/70 visual acuity caused by occult choroidal neovascularization from neovascular agerelated macular degeneration in one eye that was treated with 1.25 mg of intravitreal bevacizumab.

DISCLOSURE Dr. Fekrat has stated that he has a consultant relationship with Genentech Inc., manufacturer of a drug discussed in this article. The authors also discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products.